TREATMENT
Real-world data compares late-line treatment options for metastatic colorectal cancer — ESMO Open
A multicenter study compared outcomes of trifluridine/tipiracil (FTD-TPI) plus bevacizumab versus FTD-TPI alone or regorafenib in patients with pretreated metastatic colorectal cancer. The analysis included real-world data on effectiveness and examined whether KRAS G12 mutations affect FTD-TPI efficacy. These are treatment options typically used after standard chemotherapy regimens have stopped working.
What this means
For patients whose cancer has progressed after multiple treatments, this study provides real-world evidence comparing available late-line therapy options. Understanding how these treatments perform outside clinical trials helps patients and doctors make informed decisions about next steps.